AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
Launch of 20 new medicines expected by 2030
Launch of 20 new medicines expected by 2030
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The collaboration aims to bolster healthcare entrepreneurship
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated